Investigational Drug Information for MN-166
✉ Email this page to a colleague
What is the development status for investigational drug MN-166?
MN-166 is an investigational drug.
There have been 13 clinical trials for MN-166.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 28th 2020.
The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, National Institute on Alcohol Abuse and Alcoholism (NIAAA), and University of California, Los Angeles.
There are seven hundred and ninety-two US patents protecting this investigational drug and zero international patents.
Summary for MN-166
| US Patents | 792 |
| International Patents | 7,904 |
| US Patent Applications | 2,945 |
| WIPO Patent Applications | 1,242 |
| Japanese Patent Applications | 860 |
| Clinical Trial Progress | Phase 2 (2020-05-28) |
| Vendors | 65 |
Recent Clinical Trials for MN-166
| Title | Sponsor | Phase |
|---|---|---|
| A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder | University of Pennsylvania | Phase 2 |
| Canadian Adaptive Platform Trial for Long COVID | University Health Network, Toronto | Phase 2/Phase 3 |
| Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS | MediciNova | Phase 2 |
Clinical Trial Summary for MN-166
Top disease conditions for MN-166
Top clinical trial sponsors for MN-166
US Patents for MN-166
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MN-166 | ⤷ Sign Up | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Sign Up |
| MN-166 | ⤷ Sign Up | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | ⤷ Sign Up |
| MN-166 | ⤷ Sign Up | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | ⤷ Sign Up |
| MN-166 | ⤷ Sign Up | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | The Catholic University of America (Washington, DC) | ⤷ Sign Up |
| MN-166 | ⤷ Sign Up | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | ⤷ Sign Up |
| MN-166 | ⤷ Sign Up | Melanocortin-1 receptor-specific cyclic hexapeptides | Palatin Technologies, Inc. (Cranbury, NJ) | ⤷ Sign Up |
| MN-166 | ⤷ Sign Up | Pyrazolopyridines and pyrazolopyrimidines | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MN-166
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MN-166 | Canada | CA2961033 | 2034-09-11 | ⤷ Sign Up |
| MN-166 | European Patent Office | EP3192791 | 2034-09-11 | ⤷ Sign Up |
| MN-166 | Japan | JPWO2016039408 | 2034-09-11 | ⤷ Sign Up |
| MN-166 | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | ⤷ Sign Up |
| MN-166 | Australia | AU2012222348 | 2031-03-01 | ⤷ Sign Up |
| MN-166 | Australia | AU2012222351 | 2031-03-01 | ⤷ Sign Up |
| MN-166 | Australia | AU2013224959 | 2031-03-01 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
